CA2938928C - Use of sigma-1 receptor agonist compounds - Google Patents

Info

Publication number

CA2938928C

CA2938928C CA2938928A CA2938928A CA2938928C CA 2938928 C CA2938928 C CA 2938928C CA 2938928 A CA2938928 A CA 2938928A CA 2938928 A CA2938928 A CA 2938928A CA 2938928 C CA2938928 C CA 2938928C

Authority

CA

Canada

Prior art keywords

alkyl

diseases

agonist compound

ring

heteroatom

Prior art date

2014-02-07

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims description 185
• 229940122818 Sigma 1 receptor agonist Drugs 0.000 title 1
• 206010016654 Fibrosis Diseases 0.000 claims abstract description 155
• 230000004761 fibrosis Effects 0.000 claims abstract description 154
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 150
• 230000000750 progressive effect Effects 0.000 claims abstract description 125
• 238000011282 treatment Methods 0.000 claims abstract description 99
• 201000010099 disease Diseases 0.000 claims abstract description 93
• 208000035475 disorder Diseases 0.000 claims abstract description 57
• 230000000893 fibroproliferative effect Effects 0.000 claims abstract description 24
• 229960004038 fluvoxamine Drugs 0.000 claims description 140
• CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 139
• 239000000556 agonist Substances 0.000 claims description 131
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 113
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 113
• 210000002744 extracellular matrix Anatomy 0.000 claims description 111
• 210000001519 tissue Anatomy 0.000 claims description 99
• 125000000217 alkyl group Chemical group 0.000 claims description 86
• 210000003734 kidney Anatomy 0.000 claims description 60
• 125000003545 alkoxy group Chemical group 0.000 claims description 53
• 125000003118 aryl group Chemical group 0.000 claims description 51
• 210000000056 organ Anatomy 0.000 claims description 46
• 229920006395 saturated elastomer Polymers 0.000 claims description 45
• 125000005842 heteroatom Chemical group 0.000 claims description 42
• 229910052757 nitrogen Inorganic materials 0.000 claims description 41
• 208000017169 kidney disease Diseases 0.000 claims description 40
• 208000019693 Lung disease Diseases 0.000 claims description 34
• 230000003176 fibrotic effect Effects 0.000 claims description 34
• 125000004432 carbon atom Chemical group C* 0.000 claims description 29
• 125000002947 alkylene group Chemical group 0.000 claims description 28
• 125000000623 heterocyclic group Chemical group 0.000 claims description 28
• 210000004072 lung Anatomy 0.000 claims description 26
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 24
• 229910052736 halogen Inorganic materials 0.000 claims description 24
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
• 230000006378 damage Effects 0.000 claims description 21
• 238000007634 remodeling Methods 0.000 claims description 20
• UVSWWUWQVAQPJR-UHFFFAOYSA-N 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine Chemical compound C1=C(OC)C(OC)=CC=C1CCN1CCN(CCCC=2C=CC=CC=2)CC1 UVSWWUWQVAQPJR-UHFFFAOYSA-N 0.000 claims description 19
• RQHKZUBCUZVZEF-UHFFFAOYSA-N 1-phenyl-1-cyclohexanecarboxylic acid 2-(4-morpholinyl)ethyl ester Chemical compound C1CCCCC1(C=1C=CC=CC=1)C(=O)OCCN1CCOCC1 RQHKZUBCUZVZEF-UHFFFAOYSA-N 0.000 claims description 18
• 229910052799 carbon Inorganic materials 0.000 claims description 17
• NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 17
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 16
• 210000004185 liver Anatomy 0.000 claims description 16
• 150000002367 halogens Chemical class 0.000 claims description 15
• 230000002401 inhibitory effect Effects 0.000 claims description 15
• 208000019423 liver disease Diseases 0.000 claims description 15
• 230000003405 preventing effect Effects 0.000 claims description 15
• 208000016222 Pancreatic disease Diseases 0.000 claims description 14
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 14
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
• 208000030533 eye disease Diseases 0.000 claims description 14
• 208000024691 pancreas disease Diseases 0.000 claims description 14
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
• 210000003491 skin Anatomy 0.000 claims description 14
• -1 X is 0 Chemical group 0.000 claims description 13
• 210000003041 ligament Anatomy 0.000 claims description 13
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 13
• 150000003839 salts Chemical class 0.000 claims description 13
• 208000023275 Autoimmune disease Diseases 0.000 claims description 11
• 229910052801 chlorine Inorganic materials 0.000 claims description 11
• 230000002500 effect on skin Effects 0.000 claims description 11
• 229910052731 fluorine Inorganic materials 0.000 claims description 11
• 238000001356 surgical procedure Methods 0.000 claims description 11
• 239000003053 toxin Substances 0.000 claims description 10
• 231100000765 toxin Toxicity 0.000 claims description 10
• 108700012359 toxins Proteins 0.000 claims description 10
• 125000003342 alkenyl group Chemical group 0.000 claims description 9
• 208000030159 metabolic disease Diseases 0.000 claims description 9
• 238000002054 transplantation Methods 0.000 claims description 9
• 210000002229 urogenital system Anatomy 0.000 claims description 9
• FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 claims description 8
• BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 claims description 8
• 238000002512 chemotherapy Methods 0.000 claims description 8
• 210000005095 gastrointestinal system Anatomy 0.000 claims description 8
• 229910052739 hydrogen Inorganic materials 0.000 claims description 8
• 208000028774 intestinal disease Diseases 0.000 claims description 8
• 125000004193 piperazinyl group Chemical group 0.000 claims description 8
• SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims description 8
• 210000001508 eye Anatomy 0.000 claims description 7
• 210000002346 musculoskeletal system Anatomy 0.000 claims description 7
• 230000002980 postoperative effect Effects 0.000 claims description 7
• CFJMRBQWBDQYMK-UHFFFAOYSA-N 1-phenyl-1-cyclopentanecarboxylic acid 2-[2-(diethylamino)ethoxy]ethyl ester Chemical compound C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 CFJMRBQWBDQYMK-UHFFFAOYSA-N 0.000 claims description 6
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
• 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 6
• 239000006071 cream Substances 0.000 claims description 6
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 6
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 6
• 229960003436 pentoxyverine Drugs 0.000 claims description 6
• 125000002577 pseudohalo group Chemical group 0.000 claims description 6
• ZYXWYDDFNXBTFO-UHFFFAOYSA-N tetrazolidine Chemical compound C1NNNN1 ZYXWYDDFNXBTFO-UHFFFAOYSA-N 0.000 claims description 6
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
• 229950005050 cutamesine Drugs 0.000 claims description 5
• 239000002674 ointment Substances 0.000 claims description 5
• RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 4
• VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 claims description 4
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 4
• 239000005977 Ethylene Substances 0.000 claims description 4
• 108010081348 HRT1 protein Hairy Proteins 0.000 claims description 4
• 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims description 4
• 150000001408 amides Chemical class 0.000 claims description 4
• 125000004122 cyclic group Chemical group 0.000 claims description 4
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
• 229960002464 fluoxetine Drugs 0.000 claims description 4
• 229910052740 iodine Inorganic materials 0.000 claims description 4
• 239000006210 lotion Substances 0.000 claims description 4
• 125000003386 piperidinyl group Chemical group 0.000 claims description 4
• 230000003248 secreting effect Effects 0.000 claims description 4
• 229960002073 sertraline Drugs 0.000 claims description 4
• VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 4
• 210000005166 vasculature Anatomy 0.000 claims description 4
• QXXHHHWXFHPNOS-UHFFFAOYSA-M 1-phenylcyclohexane-1-carboxylate Chemical compound C=1C=CC=CC=1C1(C(=O)[O-])CCCCC1 QXXHHHWXFHPNOS-UHFFFAOYSA-M 0.000 claims description 3
• HELCSESNNDZLFM-UHFFFAOYSA-N 4-iodo-N-[1-(phenylmethyl)-4-piperidinyl]benzamide Chemical compound C1=CC(I)=CC=C1C(=O)NC1CCN(CC=2C=CC=CC=2)CC1 HELCSESNNDZLFM-UHFFFAOYSA-N 0.000 claims description 3
• 125000002877 alkyl aryl group Chemical group 0.000 claims description 3
• 125000004367 cycloalkylaryl group Chemical group 0.000 claims description 3
• 150000001983 dialkylethers Chemical class 0.000 claims description 3
• VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 3
• 125000002541 furyl group Chemical group 0.000 claims description 3
• 125000005843 halogen group Chemical group 0.000 claims description 3
• 229960003878 haloperidol Drugs 0.000 claims description 3
• 210000004923 pancreatic tissue Anatomy 0.000 claims description 3
• 210000005084 renal tissue Anatomy 0.000 claims description 3
• BOTHKNZTGGXFEQ-UHFFFAOYSA-N 1-(2,2-diphenyloxolan-3-yl)-n,n-dimethylmethanamine Chemical compound CN(C)CC1CCOC1(C=1C=CC=CC=1)C1=CC=CC=C1 BOTHKNZTGGXFEQ-UHFFFAOYSA-N 0.000 claims description 2
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims description 2
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 2
• 208000018380 Chemical injury Diseases 0.000 claims 1
• 210000005003 heart tissue Anatomy 0.000 claims 1
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
• 150000003053 piperidines Chemical class 0.000 claims 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 1
• 210000004027 cell Anatomy 0.000 abstract description 66
• 238000000034 method Methods 0.000 abstract description 47
• 210000000651 myofibroblast Anatomy 0.000 abstract description 46
• 230000008021 deposition Effects 0.000 abstract description 21
• 239000000203 mixture Substances 0.000 abstract description 17
• 230000002265 prevention Effects 0.000 abstract description 17
• 230000005764 inhibitory process Effects 0.000 abstract description 5
• 229940127531 Sigma-1 Receptor Agonists Drugs 0.000 abstract 2
• 206010012601 diabetes mellitus Diseases 0.000 description 112
• 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 description 91
• 101710104750 Sigma non-opioid intracellular receptor 1 Proteins 0.000 description 87
• 241000700159 Rattus Species 0.000 description 67
• ZHGMDXSHODHWHV-UHFFFAOYSA-N N-{2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethyl}-N-propylpropan-1-amine hydrochloride Chemical compound Cl.CCCN(CCC)CCC1=CC=C(OC)C(OCCC=2C=CC=CC=2)=C1 ZHGMDXSHODHWHV-UHFFFAOYSA-N 0.000 description 50
• 102000008186 Collagen Human genes 0.000 description 29
• 108010035532 Collagen Proteins 0.000 description 29
• 229920001436 collagen Polymers 0.000 description 29
• 239000003814 drug Substances 0.000 description 28
• 108090000623 proteins and genes Proteins 0.000 description 27
• 239000003981 vehicle Substances 0.000 description 27
• 238000004519 manufacturing process Methods 0.000 description 26
• 239000005557 antagonist Substances 0.000 description 25
• 229940079593 drug Drugs 0.000 description 25
• 208000005069 pulmonary fibrosis Diseases 0.000 description 25
• 208000004608 Ureteral Obstruction Diseases 0.000 description 24
• 102000004169 proteins and genes Human genes 0.000 description 24
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
• 102000016359 Fibronectins Human genes 0.000 description 22
• 108010067306 Fibronectins Proteins 0.000 description 22
• 108010006654 Bleomycin Proteins 0.000 description 20
• 241001465754 Metazoa Species 0.000 description 20
• 238000009825 accumulation Methods 0.000 description 20
• 229960001561 bleomycin Drugs 0.000 description 20
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 20
• 230000001965 increasing effect Effects 0.000 description 20
• 230000008569 process Effects 0.000 description 17
• 208000027418 Wounds and injury Diseases 0.000 description 16
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 16
• 230000000694 effects Effects 0.000 description 16
• 208000014674 injury Diseases 0.000 description 16
• 230000007423 decrease Effects 0.000 description 15
• 241000699670 Mus sp. Species 0.000 description 14
• 238000011552 rat model Methods 0.000 description 14
• 208000018522 Gastrointestinal disease Diseases 0.000 description 13
• 101150020161 flu-2 gene Proteins 0.000 description 13
• 230000006870 function Effects 0.000 description 13
• 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 12
• 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 12
• 230000018109 developmental process Effects 0.000 description 12
• 208000015181 infectious disease Diseases 0.000 description 12
• 230000001225 therapeutic effect Effects 0.000 description 12
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 11
• 238000011161 development Methods 0.000 description 11
• 208000033679 diabetic kidney disease Diseases 0.000 description 11
• 230000014509 gene expression Effects 0.000 description 11
• 108020003175 receptors Proteins 0.000 description 11
• 102000005962 receptors Human genes 0.000 description 11
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
• 102100028662 Sigma intracellular receptor 2 Human genes 0.000 description 10
• 101710109012 Sigma intracellular receptor 2 Proteins 0.000 description 10
• 239000011159 matrix material Substances 0.000 description 10
• 231100000241 scar Toxicity 0.000 description 10
• 238000010186 staining Methods 0.000 description 10
• 208000037999 tubulointerstitial fibrosis Diseases 0.000 description 10
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 9
• 208000002260 Keloid Diseases 0.000 description 9
• 230000015572 biosynthetic process Effects 0.000 description 9
• 210000004369 blood Anatomy 0.000 description 9
• 239000008280 blood Substances 0.000 description 9
• 230000001684 chronic effect Effects 0.000 description 9
• 208000020832 chronic kidney disease Diseases 0.000 description 9
• 230000001276 controlling effect Effects 0.000 description 9
• 210000002950 fibroblast Anatomy 0.000 description 9
• 210000001117 keloid Anatomy 0.000 description 9
• 230000003907 kidney function Effects 0.000 description 9
• 208000017520 skin disease Diseases 0.000 description 9
• 239000000126 substance Substances 0.000 description 9
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
• 229940109239 creatinine Drugs 0.000 description 8
• 230000006698 induction Effects 0.000 description 8
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 8
• 210000003205 muscle Anatomy 0.000 description 8
• 229910052760 oxygen Inorganic materials 0.000 description 8
• 239000001301 oxygen Substances 0.000 description 8
• ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 8
• 230000035755 proliferation Effects 0.000 description 8
• 238000012552 review Methods 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 208000002874 Acne Vulgaris Diseases 0.000 description 7
• 102000007469 Actins Human genes 0.000 description 7
• 108010085238 Actins Proteins 0.000 description 7
• 102000012422 Collagen Type I Human genes 0.000 description 7
• 108010022452 Collagen Type I Proteins 0.000 description 7
• 206010061218 Inflammation Diseases 0.000 description 7
• 206010000496 acne Diseases 0.000 description 7
• 230000009286 beneficial effect Effects 0.000 description 7
• 238000003745 diagnosis Methods 0.000 description 7
• 230000004054 inflammatory process Effects 0.000 description 7
• 238000002347 injection Methods 0.000 description 7
• 239000007924 injection Substances 0.000 description 7
• 210000001503 joint Anatomy 0.000 description 7
• 230000001575 pathological effect Effects 0.000 description 7
• 229960003073 pirfenidone Drugs 0.000 description 7
• 210000002966 serum Anatomy 0.000 description 7
• 238000012360 testing method Methods 0.000 description 7
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
• 208000032544 Cicatrix Diseases 0.000 description 6
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
• PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 6
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 6
• 231100000517 death Toxicity 0.000 description 6
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
• 230000029142 excretion Effects 0.000 description 6
• 230000003902 lesion Effects 0.000 description 6
• 230000007774 longterm Effects 0.000 description 6
• 238000005259 measurement Methods 0.000 description 6
• 238000010172 mouse model Methods 0.000 description 6
• 230000001172 regenerating effect Effects 0.000 description 6
• 230000008439 repair process Effects 0.000 description 6
• 230000037387 scars Effects 0.000 description 6
• 210000004500 stellate cell Anatomy 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• 230000000699 topical effect Effects 0.000 description 6
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
• 208000036576 Obstructive uropathy Diseases 0.000 description 5
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 5
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 5
• 230000002159 abnormal effect Effects 0.000 description 5
• 125000004429 atom Chemical group 0.000 description 5
• 201000011510 cancer Diseases 0.000 description 5
• 150000001721 carbon Chemical group 0.000 description 5
• 230000004663 cell proliferation Effects 0.000 description 5
• 230000003833 cell viability Effects 0.000 description 5
• 210000003169 central nervous system Anatomy 0.000 description 5
• 230000034994 death Effects 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 230000006735 deficit Effects 0.000 description 5
• 238000010586 diagram Methods 0.000 description 5
• 238000005516 engineering process Methods 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 230000001434 glomerular Effects 0.000 description 5
• 239000008103 glucose Substances 0.000 description 5
• 239000003102 growth factor Substances 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 239000003446 ligand Substances 0.000 description 5
• 230000037361 pathway Effects 0.000 description 5
• 239000008194 pharmaceutical composition Substances 0.000 description 5
• 230000003389 potentiating effect Effects 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 210000002460 smooth muscle Anatomy 0.000 description 5
• 239000011734 sodium Substances 0.000 description 5
• 229910052708 sodium Inorganic materials 0.000 description 5
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
• 125000001424 substituent group Chemical group 0.000 description 5
• 208000011580 syndromic disease Diseases 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 230000002485 urinary effect Effects 0.000 description 5
• 201000002327 urinary tract obstruction Diseases 0.000 description 5
• 238000001262 western blot Methods 0.000 description 5
• 208000022461 Glomerular disease Diseases 0.000 description 4
• 206010020751 Hypersensitivity Diseases 0.000 description 4
• 238000012404 In vitro experiment Methods 0.000 description 4
• 206010072877 Intestinal fibrosis Diseases 0.000 description 4
• 206010028980 Neoplasm Diseases 0.000 description 4
• 102000016611 Proteoglycans Human genes 0.000 description 4
• 108010067787 Proteoglycans Proteins 0.000 description 4
• 206010037596 Pyelonephritis Diseases 0.000 description 4
• 230000005856 abnormality Effects 0.000 description 4
• 208000026935 allergic disease Diseases 0.000 description 4
• 230000007815 allergy Effects 0.000 description 4
• 230000003620 anti-fibroproliferative effect Effects 0.000 description 4
• 230000003510 anti-fibrotic effect Effects 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• 208000019425 cirrhosis of liver Diseases 0.000 description 4
• 239000007979 citrate buffer Substances 0.000 description 4
• 238000011260 co-administration Methods 0.000 description 4
• 230000037319 collagen production Effects 0.000 description 4
• 239000002537 cosmetic Substances 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 239000000835 fiber Substances 0.000 description 4
• 231100000852 glomerular disease Toxicity 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• 230000001404 mediated effect Effects 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 230000002503 metabolic effect Effects 0.000 description 4
• 210000003668 pericyte Anatomy 0.000 description 4
• 102000013415 peroxidase activity proteins Human genes 0.000 description 4
• 108040007629 peroxidase activity proteins Proteins 0.000 description 4
• 239000002243 precursor Substances 0.000 description 4
• 230000002062 proliferating effect Effects 0.000 description 4
• 230000008929 regeneration Effects 0.000 description 4
• 238000011069 regeneration method Methods 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 108010085082 sigma receptors Proteins 0.000 description 4
• 238000013424 sirius red staining Methods 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 230000007838 tissue remodeling Effects 0.000 description 4
• NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 4
• 229960005342 tranilast Drugs 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• 230000029663 wound healing Effects 0.000 description 4
• FEQOLYDPQKHFTD-UHFFFAOYSA-N 1-(2,2-diphenyloxolan-3-yl)-n,n-dimethylmethanamine;hydrochloride Chemical compound Cl.CN(C)CC1CCOC1(C=1C=CC=CC=1)C1=CC=CC=C1 FEQOLYDPQKHFTD-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• 241000283707 Capra Species 0.000 description 3
• 102000001187 Collagen Type III Human genes 0.000 description 3
• 108010069502 Collagen Type III Proteins 0.000 description 3
• 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 3
• 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 3
• 102000016942 Elastin Human genes 0.000 description 3
• 108010014258 Elastin Proteins 0.000 description 3
• 208000004145 Endometritis Diseases 0.000 description 3
• 239000004471 Glycine Substances 0.000 description 3
• 206010018612 Gonorrhoea Diseases 0.000 description 3
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 3
• 101000836994 Homo sapiens Sigma non-opioid intracellular receptor 1 Proteins 0.000 description 3
• 206010055171 Hypertensive nephropathy Diseases 0.000 description 3
• 206010023330 Keloid scar Diseases 0.000 description 3
• 206010033645 Pancreatitis Diseases 0.000 description 3
• 206010033649 Pancreatitis chronic Diseases 0.000 description 3
• 241000700157 Rattus norvegicus Species 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 101710172711 Structural protein Proteins 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 206010000891 acute myocardial infarction Diseases 0.000 description 3
• 230000001668 ameliorated effect Effects 0.000 description 3
• 150000001413 amino acids Chemical group 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 230000001028 anti-proliverative effect Effects 0.000 description 3
• 210000002469 basement membrane Anatomy 0.000 description 3
• 230000027455 binding Effects 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 238000001516 cell proliferation assay Methods 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 229940096422 collagen type i Drugs 0.000 description 3
• 210000000805 cytoplasm Anatomy 0.000 description 3
• 231100000433 cytotoxic Toxicity 0.000 description 3
• 230000001472 cytotoxic effect Effects 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 230000004069 differentiation Effects 0.000 description 3
• 230000003292 diminished effect Effects 0.000 description 3
• 201000010582 ecthyma Diseases 0.000 description 3
• 229920002549 elastin Polymers 0.000 description 3
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
• 210000002889 endothelial cell Anatomy 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• 230000003352 fibrogenic effect Effects 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 description 3
• 230000024924 glomerular filtration Effects 0.000 description 3
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
• 125000001072 heteroaryl group Chemical class 0.000 description 3
• 230000003284 homeostatic effect Effects 0.000 description 3
• 150000002430 hydrocarbons Chemical group 0.000 description 3
• 230000001969 hypertrophic effect Effects 0.000 description 3
• 238000003364 immunohistochemistry Methods 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 102000006495 integrins Human genes 0.000 description 3
• 108010044426 integrins Proteins 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 201000006334 interstitial nephritis Diseases 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• 108020004999 messenger RNA Proteins 0.000 description 3
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
• 230000002297 mitogenic effect Effects 0.000 description 3
• 125000002950 monocyclic group Chemical group 0.000 description 3
• 238000012261 overproduction Methods 0.000 description 3
• 229960005489 paracetamol Drugs 0.000 description 3
• 239000012188 paraffin wax Substances 0.000 description 3
• 201000001474 proteinuria Diseases 0.000 description 3
• 229940044601 receptor agonist Drugs 0.000 description 3
• 239000000018 receptor agonist Substances 0.000 description 3
• 201000002793 renal fibrosis Diseases 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 201000000306 sarcoidosis Diseases 0.000 description 3
• 230000037390 scarring Effects 0.000 description 3
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
• 201000008827 tuberculosis Diseases 0.000 description 3
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• 108010072584 5-HT2B Serotonin Receptor Proteins 0.000 description 2
• 102000006969 5-HT2B Serotonin Receptor Human genes 0.000 description 2
• 108010088751 Albumins Proteins 0.000 description 2
• 102000009027 Albumins Human genes 0.000 description 2
• 239000012103 Alexa Fluor 488 Substances 0.000 description 2
• 208000024985 Alport syndrome Diseases 0.000 description 2
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• 241000193738 Bacillus anthracis Species 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 2
• 201000006082 Chickenpox Diseases 0.000 description 2
• 208000017667 Chronic Disease Diseases 0.000 description 2
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
• 208000000668 Chronic Pancreatitis Diseases 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 206010010356 Congenital anomaly Diseases 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• 208000002249 Diabetes Complications Diseases 0.000 description 2
• 206010012655 Diabetic complications Diseases 0.000 description 2
• 208000008960 Diabetic foot Diseases 0.000 description 2
• 201000009273 Endometriosis Diseases 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
• LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 2
• 208000007882 Gastritis Diseases 0.000 description 2
• 229920002683 Glycosaminoglycan Polymers 0.000 description 2
• 206010018691 Granuloma Diseases 0.000 description 2
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
• 208000018565 Hemochromatosis Diseases 0.000 description 2
• 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 2
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 2
• 208000028572 Hereditary chronic pancreatitis Diseases 0.000 description 2
• 208000031226 Hyperlipidaemia Diseases 0.000 description 2
• 206010020772 Hypertension Diseases 0.000 description 2
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
• 102000014429 Insulin-like growth factor Human genes 0.000 description 2
• 206010023421 Kidney fibrosis Diseases 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
• 206010030146 Oesophageal atresia Diseases 0.000 description 2
• 206010053159 Organ failure Diseases 0.000 description 2
• 208000031481 Pathologic Constriction Diseases 0.000 description 2
• 208000037273 Pathologic Processes Diseases 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 108010063843 Phencyclidine Receptors Proteins 0.000 description 2
• 108010050808 Procollagen Proteins 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
• 241000224526 Trichomonas Species 0.000 description 2
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
• 208000034784 Tularaemia Diseases 0.000 description 2
• 208000025865 Ulcer Diseases 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• 206010046406 Ureteric obstruction Diseases 0.000 description 2
• 208000025609 Urogenital disease Diseases 0.000 description 2
• 206010046980 Varicella Diseases 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 2
• 208000018839 Wilson disease Diseases 0.000 description 2
• 229960001138 acetylsalicylic acid Drugs 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 229940035676 analgesics Drugs 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 239000000730 antalgic agent Substances 0.000 description 2
• 230000003110 anti-inflammatory effect Effects 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 210000002565 arteriole Anatomy 0.000 description 2
• 239000010425 asbestos Substances 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 230000000975 bioactive effect Effects 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 210000002808 connective tissue Anatomy 0.000 description 2
• 230000008602 contraction Effects 0.000 description 2
• 210000004087 cornea Anatomy 0.000 description 2
• 201000003146 cystitis Diseases 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 239000006196 drop Substances 0.000 description 2
• 230000007613 environmental effect Effects 0.000 description 2
• 239000003344 environmental pollutant Substances 0.000 description 2
• 201000010063 epididymitis Diseases 0.000 description 2
• 208000008929 esophageal atresia Diseases 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 208000006275 fascioliasis Diseases 0.000 description 2
• 102000013373 fibrillar collagen Human genes 0.000 description 2
• 108060002894 fibrillar collagen Proteins 0.000 description 2
• 102000013370 fibrillin Human genes 0.000 description 2
• 108060002895 fibrillin Proteins 0.000 description 2
• 229940126864 fibroblast growth factor Drugs 0.000 description 2
• 230000009795 fibrotic process Effects 0.000 description 2
• 239000010408 film Substances 0.000 description 2
• 229960002107 fluvoxamine maleate Drugs 0.000 description 2
• IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 2
• 239000003517 fume Substances 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
• 238000002695 general anesthesia Methods 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 208000005252 hepatitis A Diseases 0.000 description 2
• 208000003215 hereditary nephritis Diseases 0.000 description 2
• 201000007162 hidradenitis suppurativa Diseases 0.000 description 2
• 230000013632 homeostatic process Effects 0.000 description 2
• 239000000017 hydrogel Substances 0.000 description 2
• 229960002591 hydroxyproline Drugs 0.000 description 2
• 229960001680 ibuprofen Drugs 0.000 description 2
• 210000002865 immune cell Anatomy 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 230000000968 intestinal effect Effects 0.000 description 2
• 238000007913 intrathecal administration Methods 0.000 description 2
• 238000011862 kidney biopsy Methods 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 238000011068 loading method Methods 0.000 description 2
• 208000024714 major depressive disease Diseases 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 229930014626 natural product Natural products 0.000 description 2
• 201000008383 nephritis Diseases 0.000 description 2
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
• 238000003305 oral gavage Methods 0.000 description 2
• 230000009054 pathological process Effects 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 2
• 230000035790 physiological processes and functions Effects 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 239000000902 placebo Substances 0.000 description 2
• 229940068196 placebo Drugs 0.000 description 2
• 231100000719 pollutant Toxicity 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 210000000512 proximal kidney tubule Anatomy 0.000 description 2
• 238000001959 radiotherapy Methods 0.000 description 2
• 230000007363 regulatory process Effects 0.000 description 2
• 230000000241 respiratory effect Effects 0.000 description 2
• 230000008458 response to injury Effects 0.000 description 2
• 210000001525 retina Anatomy 0.000 description 2
• 238000003757 reverse transcription PCR Methods 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 229910052895 riebeckite Inorganic materials 0.000 description 2
• 239000003982 sigma receptor ligand Substances 0.000 description 2
• 230000000391 smoking effect Effects 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 229960001052 streptozocin Drugs 0.000 description 2
• 210000003518 stress fiber Anatomy 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 208000006379 syphilis Diseases 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 238000007910 systemic administration Methods 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 201000005060 thrombophlebitis Diseases 0.000 description 2
• 230000030968 tissue homeostasis Effects 0.000 description 2
• 230000017423 tissue regeneration Effects 0.000 description 2
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
• 210000000626 ureter Anatomy 0.000 description 2
• 210000003708 urethra Anatomy 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
• DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
• KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
• VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 description 1
• RHPCYZLXNNRRMB-UHFFFAOYSA-N 1-phenylcyclopentane-1-carboxylic acid Chemical compound C=1C=CC=CC=1C1(C(=O)O)CCCC1 RHPCYZLXNNRRMB-UHFFFAOYSA-N 0.000 description 1
• PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
• GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
• 229940116892 5 Hydroxytryptamine 2B receptor antagonist Drugs 0.000 description 1
• 108091005479 5-HT2 receptors Proteins 0.000 description 1
• HLXHCNWEVQNNKA-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-inden-2-amine Chemical compound COC1=CC=C2CC(N)CC2=C1 HLXHCNWEVQNNKA-UHFFFAOYSA-N 0.000 description 1
• GXWNSJYVSIJRLS-UHFFFAOYSA-N 6-bromo-8-methylimidazo[1,2-a]pyrazine Chemical compound CC1=NC(Br)=CN2C=CN=C12 GXWNSJYVSIJRLS-UHFFFAOYSA-N 0.000 description 1
• 239000005541 ACE inhibitor Substances 0.000 description 1
• 101150101604 ACVR1B gene Proteins 0.000 description 1
• 102100037651 AP-2 complex subunit sigma Human genes 0.000 description 1
• 102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 description 1
• 208000020576 Adrenal disease Diseases 0.000 description 1
• 201000011374 Alagille syndrome Diseases 0.000 description 1
• 206010001580 Albuminuria Diseases 0.000 description 1
• PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
• PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
• 239000012099 Alexa Fluor family Substances 0.000 description 1
• RYVZYACBVYKUHD-UHFFFAOYSA-N Alk5 Natural products CC#CC#CCCCCC=CC(=O)NCC(C)C RYVZYACBVYKUHD-UHFFFAOYSA-N 0.000 description 1
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 108010039627 Aprotinin Proteins 0.000 description 1
• 206010003210 Arteriosclerosis Diseases 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 208000023514 Barrett esophagus Diseases 0.000 description 1
• 208000023665 Barrett oesophagus Diseases 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 238000009010 Bradford assay Methods 0.000 description 1
• 208000007257 Budd-Chiari syndrome Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 238000011740 C57BL/6 mouse Methods 0.000 description 1
• 201000002829 CREST Syndrome Diseases 0.000 description 1
• KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
• 206010007882 Cellulitis Diseases 0.000 description 1
• 241000122205 Chamaeleonidae Species 0.000 description 1
• 241000606161 Chlamydia Species 0.000 description 1
• ZCKAMNXUHHNZLN-UHFFFAOYSA-N Chlorphentermine Chemical compound CC(C)(N)CC1=CC=C(Cl)C=C1 ZCKAMNXUHHNZLN-UHFFFAOYSA-N 0.000 description 1
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
• 206010008635 Cholestasis Diseases 0.000 description 1
• 208000016216 Choristoma Diseases 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• 206010063209 Chronic allograft nephropathy Diseases 0.000 description 1
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
• 229940119334 Chymase inhibitor Drugs 0.000 description 1
• 241000272194 Ciconiiformes Species 0.000 description 1
• 206010009895 Colitis ischaemic Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 206010010317 Congenital absence of bile ducts Diseases 0.000 description 1
• 208000016758 Congenital fibrosis of extraocular muscles Diseases 0.000 description 1
• 102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
• 108010022637 Copper-Transporting ATPases Proteins 0.000 description 1
• 208000014311 Cushing syndrome Diseases 0.000 description 1
• 206010011684 Cutaneous tuberculosis Diseases 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• 206010011778 Cystinuria Diseases 0.000 description 1
• 206010011985 Decubitus ulcer Diseases 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
• 206010072268 Drug-induced liver injury Diseases 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 206010014666 Endocarditis bacterial Diseases 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000001351 Epiretinal Membrane Diseases 0.000 description 1
• 206010015218 Erythema multiforme Diseases 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
• 206010051841 Exposure to allergen Diseases 0.000 description 1
• JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
• 208000024720 Fabry Disease Diseases 0.000 description 1
• 206010016228 Fasciitis Diseases 0.000 description 1
• 241000242711 Fasciola hepatica Species 0.000 description 1
• 102000009842 Fibril-Associated Collagens Human genes 0.000 description 1
• 108010020305 Fibril-Associated Collagens Proteins 0.000 description 1
• 208000027472 Galactosemias Diseases 0.000 description 1
• 208000007465 Giant cell arteritis Diseases 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 206010018341 Gliosis Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 206010018693 Granuloma inguinale Diseases 0.000 description 1
• 108010023302 HDL Cholesterol Proteins 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 206010018852 Haematoma Diseases 0.000 description 1
• 241000590002 Helicobacter pylori Species 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 208000005331 Hepatitis D Diseases 0.000 description 1
• 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
• 208000037319 Hepatitis infectious Diseases 0.000 description 1
• 206010019799 Hepatitis viral Diseases 0.000 description 1
• 206010019837 Hepatocellular injury Diseases 0.000 description 1
• 206010056976 Hereditary pancreatitis Diseases 0.000 description 1
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
• 208000005100 Herpetic Keratitis Diseases 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000806914 Homo sapiens AP-2 complex subunit sigma Proteins 0.000 description 1
• 101100533398 Homo sapiens SIGMAR1 gene Proteins 0.000 description 1
• 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 1
• WNZBBTJFOIOEMP-UHFFFAOYSA-N Hydroxyhaloperidol Chemical compound C=1C=C(F)C=CC=1C(O)CCCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 WNZBBTJFOIOEMP-UHFFFAOYSA-N 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 208000037147 Hypercalcaemia Diseases 0.000 description 1
• 208000002682 Hyperkalemia Diseases 0.000 description 1
• 208000008852 Hyperoxaluria Diseases 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• 208000013038 Hypocalcemia Diseases 0.000 description 1
• 206010021036 Hyponatraemia Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• 206010021531 Impetigo Diseases 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 206010061216 Infarction Diseases 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 108090000176 Interleukin-13 Proteins 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 208000029523 Interstitial Lung disease Diseases 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 102000007547 Laminin Human genes 0.000 description 1
• 108010085895 Laminin Proteins 0.000 description 1
• 241000236488 Lepra Species 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
• 208000032376 Lung infection Diseases 0.000 description 1
• 208000005777 Lupus Nephritis Diseases 0.000 description 1
• 208000005446 Lupus vulgaris Diseases 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 208000008771 Lymphadenopathy Diseases 0.000 description 1
• 208000031471 Macular fibrosis Diseases 0.000 description 1
• 238000000585 Mann–Whitney U test Methods 0.000 description 1
• 206010026889 Mastitis postpartum Diseases 0.000 description 1
• 208000019255 Menstrual disease Diseases 0.000 description 1
• 208000001145 Metabolic Syndrome Diseases 0.000 description 1
• 206010027525 Microalbuminuria Diseases 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• 102000005431 Molecular Chaperones Human genes 0.000 description 1
• 108010006519 Molecular Chaperones Proteins 0.000 description 1
• 208000008955 Mucolipidoses Diseases 0.000 description 1
• 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
• 208000028781 Mucopolysaccharidosis type 1 Diseases 0.000 description 1
• 206010048654 Muscle fibrosis Diseases 0.000 description 1
• 206010073599 Myeloma cast nephropathy Diseases 0.000 description 1
• 206010051458 Myometritis Diseases 0.000 description 1
• 102000003505 Myosin Human genes 0.000 description 1
• 108060008487 Myosin Proteins 0.000 description 1
• KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
• RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
• 206010056969 Necrobiosis lipoidica diabeticorum Diseases 0.000 description 1
• 206010051606 Necrotising colitis Diseases 0.000 description 1
• 206010029148 Nephrolithiasis Diseases 0.000 description 1
• 241000208125 Nicotiana Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 241000483376 Noctua comes Species 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
• 244000061661 Orchis Species 0.000 description 1
• 241000150452 Orthohantavirus Species 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 206010049226 Oxalosis Diseases 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 206010033847 Parametritis Diseases 0.000 description 1
• 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 208000020758 Peyronie disease Diseases 0.000 description 1
• CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
• 206010034972 Photosensitivity reaction Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 206010036976 Prostatism Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 241000588769 Proteus <enterobacteria> Species 0.000 description 1
• 206010037083 Prurigo Diseases 0.000 description 1
• 208000003251 Pruritus Diseases 0.000 description 1
• 201000004613 Pseudoxanthoma elasticum Diseases 0.000 description 1
• 206010037549 Purpura Diseases 0.000 description 1
• 241001672981 Purpura Species 0.000 description 1
• 238000002123 RNA extraction Methods 0.000 description 1
• 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 description 1
• 101000885869 Rattus norvegicus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• 206010065427 Reflux nephropathy Diseases 0.000 description 1
• 102000003743 Relaxin Human genes 0.000 description 1
• 108090000103 Relaxin Proteins 0.000 description 1
• 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 206010038378 Renal artery stenosis Diseases 0.000 description 1
• 206010062237 Renal impairment Diseases 0.000 description 1
• 206010038848 Retinal detachment Diseases 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 206010057430 Retinal injury Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
• 206010038934 Retinopathy proliferative Diseases 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 241001303601 Rosacea Species 0.000 description 1
• 208000007893 Salpingitis Diseases 0.000 description 1
• 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
• 206010039792 Seborrhoea Diseases 0.000 description 1
• 229940094948 Sigma receptor agonist Drugs 0.000 description 1
• YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 208000031726 Spotted Fever Group Rickettsiosis Diseases 0.000 description 1
• 208000036038 Subretinal fibrosis Diseases 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 102100034333 Synaptic vesicular amine transporter Human genes 0.000 description 1
• 101710164184 Synaptic vesicular amine transporter Proteins 0.000 description 1
• 201000009594 Systemic Scleroderma Diseases 0.000 description 1
• 206010042953 Systemic sclerosis Diseases 0.000 description 1
• 108700012920 TNF Proteins 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• 208000001106 Takayasu Arteritis Diseases 0.000 description 1
• 208000026062 Tissue disease Diseases 0.000 description 1
• 241000960387 Torque teno virus Species 0.000 description 1
• 206010070863 Toxicity to various agents Diseases 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
• 206010046337 Urate nephropathy Diseases 0.000 description 1
• 208000033774 Ventricular Remodeling Diseases 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 229960004308 acetylcysteine Drugs 0.000 description 1
• 201000007691 actinomycosis Diseases 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 206010064930 age-related macular degeneration Diseases 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 208000002353 alcoholic hepatitis Diseases 0.000 description 1
• 206010056977 alcoholic pancreatitis Diseases 0.000 description 1
• 229960002478 aldosterone Drugs 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
• SYAKTDIEAPMBAL-UHFFFAOYSA-N aminorex Chemical compound O1C(N)=NCC1C1=CC=CC=C1 SYAKTDIEAPMBAL-UHFFFAOYSA-N 0.000 description 1
• 229950002544 aminorex Drugs 0.000 description 1
• 229960005260 amiodarone Drugs 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 230000000202 analgesic effect Effects 0.000 description 1
• QZLYKIGBANMMBK-UGCZWRCOSA-N androstane group Chemical group [C@@H]12CCC[C@@]1(C)CC[C@H]1[C@H]2CC[C@H]2CCCC[C@]12C QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 239000002870 angiogenesis inducing agent Substances 0.000 description 1
• 201000009431 angiokeratoma Diseases 0.000 description 1
• 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
• 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000001772 anti-angiogenic effect Effects 0.000 description 1
• 230000002300 anti-fibrosis Effects 0.000 description 1
• 239000000883 anti-obesity agent Substances 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 239000000043 antiallergic agent Substances 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940124433 antimigraine drug Drugs 0.000 description 1
• 239000002543 antimycotic Substances 0.000 description 1
• 239000003420 antiserotonin agent Substances 0.000 description 1
• 229960004405 aprotinin Drugs 0.000 description 1
• 208000011775 arteriosclerosis disease Diseases 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 208000009361 bacterial endocarditis Diseases 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 201000005271 biliary atresia Diseases 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 229940088623 biologically active substance Drugs 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 206010006451 bronchitis Diseases 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229960004596 cabergoline Drugs 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 206010061592 cardiac fibrillation Diseases 0.000 description 1
• 230000009787 cardiac fibrosis Effects 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 230000008568 cell cell communication Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 238000003570 cell viability assay Methods 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 206010008323 cervicitis Diseases 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 201000008240 chemical colitis Diseases 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 229950007046 chlorphentermine Drugs 0.000 description 1
• 208000003167 cholangitis Diseases 0.000 description 1
• 230000007870 cholestasis Effects 0.000 description 1
• 231100000359 cholestasis Toxicity 0.000 description 1
• 201000003988 chronic cervicitis Diseases 0.000 description 1
• 208000023652 chronic gastritis Diseases 0.000 description 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
• 239000003601 chymase inhibitor Substances 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 230000008045 co-localization Effects 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 208000008609 collagenous colitis Diseases 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 201000011635 congenital fibrosis of the extraocular muscles Diseases 0.000 description 1
• 210000001608 connective tissue cell Anatomy 0.000 description 1
• 239000002872 contrast media Substances 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• 230000001120 cytoprotective effect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 238000009795 derivation Methods 0.000 description 1
• 230000036576 dermal application Effects 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 229960002069 diamorphine Drugs 0.000 description 1
• 125000000600 disaccharide group Chemical group 0.000 description 1
• WZRZTHMJPHPAMU-UHFFFAOYSA-L disodium;(3e)-3-[(4-amino-3-sulfonatophenyl)-(4-amino-3-sulfophenyl)methylidene]-6-imino-5-methylcyclohexa-1,4-diene-1-sulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(=N)C(C)=CC1=C(C=1C=C(C(N)=CC=1)S([O-])(=O)=O)C1=CC=C(N)C(S(O)(=O)=O)=C1 WZRZTHMJPHPAMU-UHFFFAOYSA-L 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 201000008243 diversion colitis Diseases 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 201000008865 drug-induced hepatitis Diseases 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 125000001033 ether group Chemical group 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 238000013265 extended release Methods 0.000 description 1
• 235000013861 fat-free Nutrition 0.000 description 1
• 229960001582 fenfluramine Drugs 0.000 description 1
• 230000003619 fibrillary effect Effects 0.000 description 1
• 230000002600 fibrillogenic effect Effects 0.000 description 1
• 210000000630 fibrocyte Anatomy 0.000 description 1
• 206010016629 fibroma Diseases 0.000 description 1
• 239000002657 fibrous material Substances 0.000 description 1
• 230000001497 fibrovascular Effects 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000000834 fixative Substances 0.000 description 1
• 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 230000007387 gliosis Effects 0.000 description 1
• 201000004541 glycogen storage disease I Diseases 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 239000008266 hair spray Substances 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 229940037467 helicobacter pylori Drugs 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 208000027700 hepatic dysfunction Diseases 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 210000004024 hepatic stellate cell Anatomy 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 230000002363 herbicidal effect Effects 0.000 description 1
• 239000004009 herbicide Substances 0.000 description 1
• 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 210000004276 hyalin Anatomy 0.000 description 1
• 230000000148 hypercalcaemia Effects 0.000 description 1
• 201000005991 hyperphosphatemia Diseases 0.000 description 1
• 230000000705 hypocalcaemia Effects 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 238000012308 immunohistochemistry method Methods 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• 201000007119 infective endocarditis Diseases 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 210000004347 intestinal mucosa Anatomy 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 108091008582 intracellular receptors Proteins 0.000 description 1
• 102000027411 intracellular receptors Human genes 0.000 description 1
• 238000007919 intrasynovial administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 230000005865 ionizing radiation Effects 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 108010028309 kalinin Proteins 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 210000000690 kidney interstitial fibroblast Anatomy 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 238000002350 laparotomy Methods 0.000 description 1
• 231100000225 lethality Toxicity 0.000 description 1
• 108010052968 leupeptin Proteins 0.000 description 1
• GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
• 208000020442 loss of weight Diseases 0.000 description 1
• 208000018555 lymphatic system disease Diseases 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 210000003584 mesangial cell Anatomy 0.000 description 1
• 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• MCPLVIGCWWTHFH-UHFFFAOYSA-L methyl blue Chemical compound [Na+].[Na+].C1=CC(S(=O)(=O)[O-])=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[NH+]C=2C=CC(=CC=2)S([O-])(=O)=O)C=2C=CC(NC=3C=CC(=CC=3)S([O-])(=O)=O)=CC=2)C=C1 MCPLVIGCWWTHFH-UHFFFAOYSA-L 0.000 description 1
• 229960001186 methysergide Drugs 0.000 description 1
• 108091070501 miRNA Proteins 0.000 description 1
• 239000002679 microRNA Substances 0.000 description 1
• 210000003632 microfilament Anatomy 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 238000013425 morphometry Methods 0.000 description 1
• 239000012120 mounting media Substances 0.000 description 1
• 208000020468 mucolipidosis III alpha/beta Diseases 0.000 description 1
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
• 229960004866 mycophenolate mofetil Drugs 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 125000006606 n-butoxy group Chemical group 0.000 description 1
• 201000008043 necrobiosis lipoidica Diseases 0.000 description 1
• 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
• 201000003142 neovascular glaucoma Diseases 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
• 229960000564 nitrofurantoin Drugs 0.000 description 1
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 230000000414 obstructive effect Effects 0.000 description 1
• 208000005207 oral submucous fibrosis Diseases 0.000 description 1
• 238000011474 orchiectomy Methods 0.000 description 1
• 201000005737 orchitis Diseases 0.000 description 1
• 230000004768 organ dysfunction Effects 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 230000036407 pain Effects 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 235000010603 pastilles Nutrition 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000009745 pathological pathway Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 210000003899 penis Anatomy 0.000 description 1
• YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
• 229960004851 pergolide Drugs 0.000 description 1
• 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
• 208000010182 perinephritis Diseases 0.000 description 1
• 238000012302 perinuclear staining Methods 0.000 description 1
• KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
• 206010034674 peritonitis Diseases 0.000 description 1
• NHASTOMELKHZLY-UHFFFAOYSA-N phenyl cyclopentanecarboxylate Chemical compound C1CCCC1C(=O)OC1=CC=CC=C1 NHASTOMELKHZLY-UHFFFAOYSA-N 0.000 description 1
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
• 125000004344 phenylpropyl group Chemical group 0.000 description 1
• 229960002036 phenytoin Drugs 0.000 description 1
• 230000036211 photosensitivity Effects 0.000 description 1
• 238000000053 physical method Methods 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 206010035653 pneumoconiosis Diseases 0.000 description 1
• 201000006292 polyarteritis nodosa Diseases 0.000 description 1
• 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
• 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
• 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 201000007094 prostatitis Diseases 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 238000000164 protein isolation Methods 0.000 description 1
• 239000012460 protein solution Substances 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 208000023558 pseudoxanthoma elasticum (inherited or acquired) Diseases 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 201000004537 pyelitis Diseases 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 238000011897 real-time detection Methods 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 239000003237 recreational drug Substances 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 239000006215 rectal suppository Substances 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 239000001044 red dye Substances 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 238000012959 renal replacement therapy Methods 0.000 description 1
• 230000036454 renin-angiotensin system Effects 0.000 description 1
• 230000001084 renoprotective effect Effects 0.000 description 1
• 210000004994 reproductive system Anatomy 0.000 description 1
• 210000005000 reproductive tract Anatomy 0.000 description 1
• 230000004264 retinal detachment Effects 0.000 description 1
• 201000004700 rosacea Diseases 0.000 description 1
• 201000004409 schistosomiasis Diseases 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 208000010157 sclerosing cholangitis Diseases 0.000 description 1
• 208000008742 seborrheic dermatitis Diseases 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 239000002891 serotonin 2B antagonist Substances 0.000 description 1
• 239000000952 serotonin receptor agonist Substances 0.000 description 1
• 208000007056 sickle cell anemia Diseases 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 239000000779 smoke Substances 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 208000000995 spontaneous abortion Diseases 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 230000036262 stenosis Effects 0.000 description 1
• 208000037804 stenosis Diseases 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 229910021653 sulphate ion Inorganic materials 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 239000003356 suture material Substances 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 206010043207 temporal arteritis Diseases 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 210000000115 thoracic cavity Anatomy 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 230000025934 tissue morphogenesis Effects 0.000 description 1
• 239000002407 tissue scaffold Substances 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 231100000167 toxic agent Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 239000003440 toxic substance Substances 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000002110 toxicologic effect Effects 0.000 description 1
• 231100000027 toxicology Toxicity 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 206010044325 trachoma Diseases 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 210000001215 vagina Anatomy 0.000 description 1
• 239000006216 vaginal suppository Substances 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 208000005991 vascular hyalinosis Diseases 0.000 description 1
• 201000001862 viral hepatitis Diseases 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 230000001792 virilizing effect Effects 0.000 description 1
• 208000010484 vulvovaginitis Diseases 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 230000036642 wellbeing Effects 0.000 description 1
• 230000037314 wound repair Effects 0.000 description 1
• 229960001600 xylazine Drugs 0.000 description 1
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1